ClinicalTrials.gg
RecruitingNCT06862089Updated Jun 15, 2025

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

An observational study in Retained Products of Conception, Miscarriage and Conservative Management, sponsored by Fu Xing Hospital, Capital Medical University. Recruiting at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Fu Xing Hospital, Capital Medical University · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Abortion, Spontaneous with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Abortion, Spontaneous · China.

Planned enrollment
10th of 12
120 · median 200
Started
2024
the only one that year
Observational
12 of 15
2 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Fu Xing Hospital, Capital Medical University

Among the 15 studies in Abortion, Spontaneous with a site in China, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2024, is one of 12 observational ones, and was the 13th registered.

Abortion, Spontaneous

221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.

Browse Abortion, Spontaneous studies →

Open to participants now

4 of the 15 studies in Abortion, Spontaneous with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Abortion, Spontaneous with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV).

The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment? Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.

03

Conditions studied

  • Retained Products of Conception
  • Miscarriage
  • Conservative Management

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population of who visited the outpatient department of the hysteroscopy center of our hospital from October 2024 to October 2026 and were provisionally diagnosed as " retained products of conception (RPOC)" based on their history and symptoms.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recent history of miscarriage or delivery (within the past 8 weeks)
  • Strong willingness to undergo conservative management
  • Hemodynamically stable
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Heavy vaginal bleeding (requiring immediate surgical intervention)
  • Active pelvic or systemic infection (e.g., fever >38°C, elevated CRP/WBC)
  • Severe dysfunction of vital organs (heart, liver, or kidney)
  • Known drug allergies or to proposed medications (e.g., misoprostol intolerance)
  • Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)
  • Placenta accreta spectrum disorders diagnosed during current pregnancy
  • History of uterine artery embolization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The disappearance rate of RPOC

    The definition of "the disappearance rate of RPOC" refers to the absence of significant residual trophoblastic tissue as indicated by ultrasound examination

    Time frame: After conservative treatment, transvaginal ultrasound was performed at the end of the second menstrual cycle (calculated from the first day of menses, 28-30 days per cycle) to assess RPOC resolution

Secondary outcomes

  1. the disappearance rate of EMV

    The definition of "the disappearance rate of EMV" refers to a PSV (Peak Systolic Velocity) of less than 20 cm/s or its complete disappearance as indicated by Ultrasound Doppler examination.

    Time frame: Immediately after the completion of conservative treatment

07

Study locations

1 of 1 sites recruiting
  • Hysteroscopy Center, Fuxing Hospital, Capital Medical University
    Beijing, 100086, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 43 observational studies under Abortion, Spontaneous, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 91. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Mar 6, 2025
StartActual
Oct 23, 2024
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06862089
Lead sponsor
Fu Xing Hospital, Capital Medical University
Responsible party
Huang Rui (MD,Gynecologist, Department of Hysteroscopy Center, Fu Xing Hospital, Capital Medical University) — Principal investigator
First posted
Mar 6, 2025
Start date
Oct 23, 2024
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 15, 2025

Study contacts

Rui Huang
Contact
blueberry0801@foxmail.com
+86 18610317613

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion